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Edited by Laszlo NagyAbstract Activation of peroxisome proliferator-activated
receptor-a (PPAR-a) has been recently reported to inhibit vascu-
lar inﬂammatory response and prevent cardiac hypertrophy.
However, it is unclear how the activation of PPAR-a regulates
hypertrophic response. In the present study, we found that appli-
cation of fenoﬁbrate and overexpression of PPAR-a inhibited
endothelin-1 (ET-1)-induced phosphorylation of protein kinase
B (Akt) at Ser473 and glycogen synthase kinase3b (GSK3b) at
Ser9, and prevented ET-1-induced nuclear translocation of
NFATc4 in cardiomyocytes. Moreover, co-immunoprecipitation
studies showed that fenoﬁbrate strongly induced the association
of nuclear factor of activated T cells (NFATc4) with PPAR-a.
These results suggest that activation of PPAR-a inhibits ET-1-
induced cardiac hypertrophy through regulating PI3K/Akt/
GSK3b and NFAT signaling pathways.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Peroxisome proliferator-activated receptor-a (PPAR-a) is a
ligand-activated nuclear receptor which plays important roles
in lipid metabolism and glucose homeostasis [1]. PPAR-a also
participates in the pathophysiology of hypertensive heart dis-
eases [2–4]. Activation of PPAR-a inhibits cardiac hypertro-
phy via various signaling pathways [5–7]. Fenoﬁbrate, a
PPAR-a activator, was reported to prevent endothelin-1
(ET-1)-induced cardiac hypertrophy via inhibition of p38
and c-Jun NH2-terminal kinase signal pathways [5,6]. OtherAbbreviations: PPAR-a, peroxisome proliferator-activated receptor-a;
PI3K, phosphoinositide 3-kinase; GSK, glycogen synthase kinase;
Akt, protein kinase B; NFAT, nuclear factor of activated T cells; Ser,
serine; FGF, ﬁbroblast growth factor; VEGF, vascular endothelial
growth factor; ET-1, endothelin-1; S.E.M., standard error mean; LY,
LY294002; CsA, cyclosporin A; Feno, fenoﬁbrate
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doi:10.1016/j.febslet.2007.06.017activators of PPAR-a inhibit cardiac hypertrophy through
enhancing physical interactions between PPAR-a and the
p65 subunit of NF-jB [7]. However, it is not known if other
signaling molecules are also involved in the inhibitory eﬀects
of PPAR-a on cardiac hypertrophy. Recent ﬁndings suggest
that glycogen synthase kinase3b (GSK3b), an important
endogenous negative regulator of cardiac hypertrophy, is a po-
tential candidate [8]. ET-1 inhibits GSK3b activity through the
activation of phosphoinositide 3-kinase (PI3K)/protein kinase
B (Akt) pathway and subsequent phosphorylation of GSK3b
at serine 9 residues [9]. Inactivated GSK3b modulates the
activity of AP-1 and nuclear translocation of NFATs [10–
12]. NFATs may play important roles in ET-1-induced cardiac
hypertrophy. Activation of NFATc4 has been shown to result
from endocrine inducers of cardiomyocyte hypertrophy such
as angiotensinII [13] while the expression of a dominant-nega-
tive NFATc4 protein blocks the hypertrophy induced by ET-1
[14].
It is not known if Akt/GSK3b and NFATs are involved in
the inhibitory eﬀect of PPAR-a in ET-1 induced cardiac hyper-
trophy although PPARs suppress the activities of several tran-
scriptional factors including NFATs and AP-1 to exert their
anti-inﬂammatory eﬀects [15] while fenoﬁbrate has recently
been shown to inhibit ﬁbroblast growth factor (FGF)- and
vascular endothelial growth factor (VEGF)-induced activation
of Akt, an upstream kinase of GSK3b, in endothelial cells
[16,17]. In the present study, we found that the activation of
PPAR-a inhibited ET-1-induced cardiomyocyte hypertrophy,
phosphorylation of Akt/GSK3b and nuclear translocation of
NFATc4. Moreover, our results showed that fenoﬁbrate en-
hanced the association between NFATc4 and PPAR-a. Taken
together, these data suggest that the inactivation of PI3K/Akt/
GSK3b and NFAT signaling pathways may contribute to the
inhibitory eﬀect of PPAR-a on ET-1-induced cardiac hypertro-
phy.2. Materials and methods
2.1. Materials
Fenoﬁbrate, endothelin-1, PI3K inhibitor (LY294002), calcineurin
inhibitor (cyclosporin A) were purchased from Sigma–Aldrich. [3H]
leucine was obtained from Beijing Atom High Tech Co., Ltd. The
pMD18-T vector was purchased from Takara, and pEGFP-N3 vector
was from BD Biosciences Clontech.blished by Elsevier B.V. All rights reserved.
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Rat PPAR-a was cloned from rat cardiac myocytes cDNA using the
following primers: PPAR-a (sense), 5 0-CTCGAGCAATGGTGG-
ACACAGAGAG-3 0; PPAR-a (antisense), 5 0-GTCGACGTACAT-
GTCTCTGTAGATCTCT-3 0. The PCR product was subcloned into
pMD18-T vector (Takara), after sequence analysis, target fragment
was cloned into the mammalian expression vector pEGFP-N3 to ob-
tain a PPAR-a green ﬂuorescent protein construct (PPAR-a-pEGFP-
N3, see Supplementary data).
For transient transfection, cardiac myocytes in 24-well plates
(2 · 105cells/well) were transiently transfected with 1.0 lg of PPAR-
a-pEGFP-N3 or pEGFP-N3 plasmid (as transfection control) using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions.
2.3. Primary culture of rat cardiac myocytes
Primary culture of cardiac myocytes was prepared as described pre-
viously [18]. Ventricular cardiac myocytes were isolated from 2 to 3-
day-old Sprague–Dawley rats, cultured in DMEM medium with 10%
fetal bovine serum and 0.1 mmol/L 5-bromodeoxyuridine. After 48 h
of incubation, cardiac myocytes were cultured in serum-free DMEM
supplemented with 0.1% fatty acid-free BSA for 24 h before used.
2.4. Incorporation of [3H] leucine
Cardiac myocytes cultured in 24-well plates were serum starved for
24 h, pretreated for 1 h with fenoﬁbrate (10 lmol/L), LY294002
(10 lmol/L), or cyclosporin A (CsA) (500 nmol/L) respectively, and
then treated with 10 nmol/L ET-1 in serum-free medium in the pres-
ence of [3H] leucine (1.0 lCi/mL ) for 24 h. At the end of the incuba-
tion, the plates were quickly washed twice with ice-cold phosphate
buﬀered saline (PBS), kept for 1 h with ice-cold 5% (v/v) trichloroacetic
acid at 4 C. After washed with PBS, precipitates were solubilized in
0.1 mol/L of NaOH. The radioactivity was determined by liquid scin-
tillation spectrometry.
2.5. Western blot analysis
Western blot analysis of total protein (for signal molecules) and
nuclear protein (for NFATc4 and histone H1) isolated from cardiac
myocytes was performed as previously described [19]. The following
antibodies were used in this study: rabbit polyclonal antibodies against
phospho-Akt (Ser473), Akt, phospho-GSK3b (Ser9), GSK3b, and
NFATc4 (1:1000 dilution, Cell Signaling Technology Inc.); mouse
monoclonal antibodies against PPAR-a (1:500 dilution, Sigma), a-
tubulin (1:10000 dilution, Sigma) and goat polyclonal antibody anti-
histone H1 (sc-8616). The phosphorylation of Akt or GSK3b was
presented as ratio of phosphorylated to unphosphorylated Akt or
GSK3b.Fig. 1. Fenoﬁbrate attenuated ET-1-induced phosphorylation of Akt/GSK3b
Fenoﬁbrate inhibited ET-1-induced phosphorylation of Akt/GSK3b. (C) ET
Values are presented as means ± S.E.M., obtained from three independent e2.6. Immunoﬂuorescence and confocal microscopic assay
Cardiac myocytes grown on glass coverslips were serum starved for
24 h followed by 1 h treatment with fenoﬁbrate (10 lmol/L). Subse-
quently, cells were stimulated by ET-1 (10 nmol/L) for 3 h. Double
immunoﬂuorescent staining was performed using a speciﬁc antibody
against NFATc4, then with a FITC-conjugated goat anti-rabbit IgG
(green) plus Hoechst33258 (blue).
In another set of experiment, cardiac myocytes grown on glass cov-
erslips in six-well dishes were transfected with or without PPAR-a-
pEGFP-N3 (green) for 24 h. After serum starvation of these transfec-
ted cells for 24 h, cells were treated with fenoﬁbrate (10 lmol/L) for 1 h
and subsequently with ET-1 (10 nmol/L) for 3 h. Triple immunoﬂuo-
rescent staining was performed using Cy3-conjugated goat anti-rabbit
IgG (red), plus Hoechst33258 (blue). Cells were observed using a ﬂuo-
rescence microscope Olympus Fluoview FV500.
2.7. Co-immunoprecipitation
NFATc4 was immunoprecipitated by incubating total lysates
(100 lg protein) with an anti-NFATc4 antibody, or normal rabbit
IgG [20]. Formed immunocomplexes were isolated by protein A-aga-
rose beads (Santa Cruz Biotechnology) and separated by 10% SDS–
polyacrylamide gel electrophoresis and then PPAR-a or NFATc4 were
detected by Western blotting using an anti-PPAR-a or an anti-
NFATc4 antibody.
2.8. Statistical analysis
Data were presented as means ± S.E.M. Multiple group compari-
sons test was performed with one-way analysis of variance (ANOVA)
followed by a post hoc test. Among the various treatment groups, dif-
ferences were considered signiﬁcant with P < 0.05.3. Results
3.1. Fenoﬁbrate inhibited ET-1-induced phosphorylation of Akt
and GSK3b
To study the underlying mechanisms of inhibitory eﬀect of
fenoﬁbrate on the ET-1-induced hypertrophy, the eﬀects of
ET-1 and fenoﬁbrate on the PI3K/Akt/GSK3b pathway were
investigated. As shown in Fig. 1A, the levels of phosphoryla-
tion of Akt and GSK3b were increased after 1, 3, 6 h of ET-
1 (10 nmol/L) stimulation and reached the peak value at 3 h.
Pretreatment with fenoﬁbrate (10 lmol/L) for 1 h markedly
inhibited ET-1-induced phosphorylation of Akt and GSK3b. (A) Time course of ET-1-induced phosphorylation of Akt/GSK3b. (B)
-1-induced phosphorylation of Akt/GSK3b is PI3-kinase dependent.
xperiments. *P < 0.05, **P < 0.01 vs. control, # #P < 0.01 vs. ET-1.
Fig. 2. Fenoﬁbrate and PI3K inhibitor, LY294002, inhibited ET-1-
induced [3H] leucine uptake in cardiac myocytes. Cardiac myocytes
were pretreated with fenoﬁbrate (10 lmol/L), LY294002 (10 lmol/L),
or CsA (500 nmol/L), respectively, and then stimulated by 10 nmol/L
ET-1 and co-incubated with [3H] leucine (1 lCi/ml) for 24 h before
harvest. [3H] leucine uptake was determined by liquid scintillation
counting. Fenoﬁbrate and LY294002 inhibited ET-1-induced [3H]
leucine uptake in cardiac myocytes while CsA had no eﬀect. Data are
expressed as means ± S.E.M. of three independent preparations of
cells. Four experiments were performed in each cell prepara-
tion.**P < 0.01 vs. control; #P < 0.05 vs. ET-1.
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and GSK3b, which were insensitive to CsA (500 nmol/L,
Fig. 1C), was blocked by a speciﬁc PI3K inhibitor,
LY294002 (10 lmol/L). LY294002 and fenoﬁbrate also
blocked the hypertrophy eﬀect (incorporation of [3H] leucine)
of ET-1 on cardiac myocytes (Fig. 2).
3.2. Overexpression of PPAR-a inhibited ET-1-induced
phosphorylation of Akt and GSK3b
To further investigate the eﬀects of PPAR-a on ET-1-in-
duced phosphorylation of Akt and GSK3b, PPAR-a-
EGFPN3 plasmid was constructed and used as described inFig. 3. Overexpression of PPAR-a inhibited ET-1-induced phosphorylation o
PPAR-a-EGFPN3, the expression and subcellular location of PPAR-a and
Section 2. (A) PPAR-a was mainly located in nucleus. (B) Overexpression of P
1. Data are expressed as means ± S.E.M. from three experiments. **P < 0.01Section 2. As shown in Fig. 3A, PPAR-a was predominantly
present in the nucleus in PPAR-a-EGFPN3 transfection cells.
Treatment of these cells with fenoﬁbrate enhanced the nuclear
localization of PPAR-a (Fig. 3A). Moreover, PPAR-a-
EGFPN3 transfection signiﬁcantly increased both mRNA
and protein expression of PPAR-a in cardiac myocytes (see
Supplementary Fig. 2). Overexpression of PPAR-a alone or
the combination of overexpression of PPAR-a with fenoﬁbrate
markedly inhibited ET-1-stimulated phosphorylation of Akt
and GSK3b (Fig. 3B).3.3. Fenoﬁbrate and overexpression of PPAR-a inhibited nuclear
translocation of NFATc4 induced by ET-1
We next examined the eﬀects of ET-1, fenoﬁbrate and over-
expression of PPAR-a on the expression and cellular localiza-
tion of NFATc4 by immunoﬂuorescence analysis. As shown in
Fig. 4A and B, ET-1 stimulation markedly increased the trans-
location of NFATc4 from the cytoplasm to the nucleus while
fenoﬁbrate (10 lmol/L) prevented such translocation. These
results were also conﬁrmed by Western blot analysis. Consis-
tent with the negative regulatory eﬀect of PPAR-a, the overex-
pression of PPAR-a-EGFPN3 decreased the nuclear
expression of NFATc4 in hypertrophic cardiac myocytes in-
duced by ET-1 (Fig. 4C and D).3.4. Fenoﬁbrate enhanced the association of PPAR-a with
NFATc4 in cardiomyocyte
Knowing that the activation of PPAR-a is able to regulate
the subcellular localization of NFATc4, we next examined
the interaction of PPAR-a with NFATc4 in cardiac myocytes
and the eﬀect of PPAR-a activator on the interaction. Fig. 5
shows that the interactions between PPAR-a and NFATc4
were constitutively detectable while fenoﬁbrate dramatically
increased the interaction between NFATc4 and PPAR-a. No
protein was immunoprecipitated with control IgG (data not
shown).f Akt and GSK3b. After 48 h transient transfection with EGFPN3 and
the phosphorylation of Akt/GSK3b were determined as described in
PAR-a attenuated the phosphorylation of Akt/GSK3b induced by ET-
vs. control; # #P < 0.01 vs. ET-1.
Fig. 4. Fenoﬁbrate (A and B) and overexpression of PPAR-a (C and D) inhibited nuclear translocation of NFATc4 induced by ET-1. (A) Double
immunoﬂuorescent staining for the eﬀect of fenoﬁbrate on nuclear localization of NFATc4. Blue – Hoechst33258 staining; Green – NFATc4. Scale
bar: 50 lm. (B) Western blot analysis for A; (C) Triple immunoﬂuorescent staining for the eﬀect of overexpressed PPAR-a on nuclear localization of
NFATc4. Green – GFP; Blue – Hoechst33258 staining; Red – NFATc4. Scale bar: 50 lm. (D) Western blot analysis for C. Data were obtained from
three independent experiments. **P < 0.01 vs. control; # #P < 0.01 vs. ET-1.
Fig. 5. Fenoﬁbrate enhanced the association of PPAR-a and
NFATc4. Cardiac myocytes were pretreated with fenoﬁbrate
(10 lmol/L) for 1 h followed by stimulation with ET-1 (10 nmol/L)
for 3 h. The association of PPAR-a with NFATc4 was determined as
described in Section 2. The interactions between PPAR-a and
NFATc4 were constitutively detectable while fenoﬁbrate dramatically
increased the interaction between NFATc4 and PPAR-a. Immuno-
precipitation (IP) displayed was representative of three independent
experiments.
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ET-1 is a potent growth factor that is able to induce cardiac
hypertrophy [21]. However, the underlying mechanisms of the
hypertrophy eﬀect of ET-1 are still not fully elucidated. One of
the possible mechanisms is that ET-1 stimulates the activation
of PI3K/Akt/GSK3b pathway and inactivates nuclear receptor
PPAR-a, leading to the hypertrophy of cardiac myocytes. ET-
1 may activate Akt through PI3Kc110/PDK pathway [22]. Acti-
vation of Akt leads to the phosphorylation of GSK3b at serine
9 and its inactivation. Inactivation of GSK3b by phosphoryla-
tion is important to induce hypertrophy as it modulates the nu-
clear translocation of NFAT and the activation of AP-1, an
important process leading to cardiac hypertrophy. In addition,
the activation of Akt mediates the down-regulation of PPAR-a
[23]. Down-regulation of PPAR-a weakens the anti-hypertro-
phy eﬀect of PPAR-a activation which has been reported to in-
R. Li et al. / FEBS Letters 581 (2007) 3311–3316 3315hibit ET-1 production by inhibiting AP-1 signaling pathway in
cardiac myocytes [5].
In support of this hypothesis, our data show that the appli-
cation of ET-1 to cardiac myocytes stimulates the phosphory-
lation of Akt and its downstream target GSK3b by the PI3K-
dependent pathway. Moreover, our results show that the treat-
ment of cardiac myocytes with ET-1 decreases the expression
of PPAR-a (data not shown). Finally, we provide evidence
that ET-1 stimulates the nuclear translocation of NFATc4.
In this study, we conﬁrm that the activation of PPAR-a by
fenoﬁbrate is able to inhibit ET-1-induced cardiac myocyte
hypertrophy (see Supplementary Fig. 1). Moreover, we ob-
serve that the activation of PPAR-a signiﬁcantly inhibits the
ET-1-induced activation of Akt/GSK3b and NFAT pathways
in cultured rat cardiac myocytes. This ﬁnding suggests the
involvement of this signaling pathway in the inhibitory eﬀect
of activated PPAR-a on cardiac hypertrophy. PPAR-a activa-
tor may mimic the eﬀect of PI3K inhibitor by inhibiting the
activation of PI3K/PDK1 which blocks the phosphorylation
of Akt and its downstream target GSK3b induced by ET-1.
Dephosphorylation of GSK3b activates this kinase, leading
to the inhibition of ET-1-induced expression and nuclear
translocation of NFAT, and ﬁnally the inhibition of hypertro-
phy. This hypothesis is supported by the following evidence:
(1) LY294002 blocks ET-1-induced phosphorylation of Akt
and GSK3b and hypertrophy; (2) fenoﬁbrate and overexpres-
sion of PPAR-a inhibits ET-1-induced phosphorylation of Akt
and GSK3b, as well as ET-1-stimulated expression and nuclear
translocation of NFATc4; and (3) fenoﬁbrate enhances the
association between NFATc4 and PPAR-a, which is a li-
gand-dependent transcription inhibitory complex in cardiac
myocytes.
NFATc4 plays a crucial role in cardiomyocyte hypertrophy.
NFAT phosphorylation by GSK3b causes the redistribution of
NFAT from the nucleus to the cytoplasm, resulting in the sub-
sequent inhibition of NFAT-mediated transcription [8,24]. The
present study shows that ET-1 can induce the nuclear translo-
cation of NFATc4, which is prevented by PPAR-a activation.
It has been reported that two distinct NFAT binding elements
are located in the PPAR-c2 gene promoter [25]. PPAR-c forms
a transcriptionally inhibitory complex with NFAT, and inhib-
its NFAT transactivation in a ligand-dependent manner [26].
As PPAR-a and PPAR-c share 60–80% homology in their li-
gand- and DNA-binding domains [27], we speculate that
PPAR-a may interact with NFAT and inhibit its DNA bind-
ing activity, leading to the inhibition of hypertrophy. Consis-
tent with this notion, our results show a strong association
between PPAR-a and NFATc4 in cardiac myocytes when
the receptor is activated.
Therefore, the anti-hypertrophy eﬀect of PPAR-a activation
is probably caused by some or all of the following mechanisms:
(a) PPAR-a activator mimics the eﬀect of PI3K inhibition, pre-
vents GSK3b inactivation, potentiates GSK3b negative regula-
tion on hypertrophic cardiomyocytes; (b) PPAR-a activator
impedes ET-1-induced NFATc4 nuclear accumulation and
negatively contributes to NFATc4 activation; and (c) PPAR-
a activator induces a strong association of NFATc4 with
PPAR-a, thus inhibits NFAT-dependent hypertrophic gene
transcription.
In summary, our results indicate that PI3K/Akt/GSK3b and
NFAT signaling pathways are involved in mediating PPAR-ainhibition of ET-1-induced cardiac myocyte hypertrophy. ET-
1 activates these signaling pathways to induce cardiac hyper-
trophy while their inhibition by the activation of PPAR-a
can inhibit ET-1-induced cardiac hypertrophy.
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